cb-5339
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jun 19, 2020 (NCT04372641)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
VCP inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04402541 | Phase 1 | Jun 30, 2020 | Cleave Biosciences, Inc. |
| NCT04372641 | Phase 1 | Jun 19, 2020 | National Cancer Institute (NCI), National Institutes of Health (NIH) |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cleave Biosciences, Inc. | For profit | 1 | 1 | 1 | 2020 |
| National Cancer Institute (NCI) | Government | 1 | 1 | 1 | 2020 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2020 |
3 organizations
Page 1 / 1